Alpha Tau Medical Q2 2026 Earnings Report

Alpha Tau Medical EPS Results

• Actual EPS: -$0.50
• Consensus EPS: -$0.14
• Beat/Miss: Missed by -$0.36
• One Year Ago EPS: N/A

Alpha Tau Medical Revenue Results

• Actual Revenue: $0.10 million
• Expected Revenue: $0.14 million
• Beat/Miss: Missed by -$44.00 thousand
• YoY Revenue Growth: N/A

Alpha Tau Medical Announcement Details

• Quarter: Q2 2026
• Date: 8/10/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Alpha Tau Medical (NASDAQ:DRTS) is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors. Alpha DaRT implants release alpha-emitting atoms that diffuse a few millimeters into the tumor, providing localized radiation doses that have shown promising preclinical and early clinical anti‐tumor activity. Alpha Tau Medical has secured Breakthrough Device designation from the U.S. Food and Drug Administration for certain cancer types and is advancing its pipeline through multi‐center trials in Europe and Israel.

Alpha Tau Medical collaborates with major oncology centers and academic institutions to conduct its clinical programs and to explore combination approaches with immunotherapies and other treatment modalities. The company has expanded its operational footprint beyond Israel, engaging regulatory and commercial partners in Europe while preparing for potential U.S. market entry. Through its focused R&D efforts and strategic alliances, Alpha Tau Medical seeks to establish alpha‐particle brachytherapy as a new standard of care for patients with challenging solid tumors.